Print
Email
Print Edition Stories
Funding drugs for rare diseases
MHT's Marc Songini: RI plans launch of cord blood center
Rodney Brown on NECN: Hacking into medical devices
Boston Scientific Corp. on Monday said European regulators have approved its Promus Element stent — the latest version of the company’s drug-coated stent technology meant to prop open previously clogged arteries.
The new Promus Element stents replace the current stents, which were made under an agreement that Boston Scientific (NYSE: BSX) has with Abbott Laboratories (NYSE: ABT). That agreement is set to expire soon.
Natick-based Boston Scientific will begin marketing the Promus Element system immediately in the European Union. The company says the Promus Element includes innovations including a proprietary platinum chromium alloy that has greater strength and flexibility than older alloys.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
